SANTA CLARA, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended September 30, 2020.
Read this article:
Shockwave Medical Reports Third Quarter 2020 Financial Results
VERSATILE-002 Trial for First Line Treatment of Recurrent/Metastatic Head and Neck Cancer with Combination PDS0101-KEYTRUDA® is Now Open and Recruiting Patients VERSATILE-002 Trial for First Line Treatment of Recurrent/Metastatic Head and Neck Cancer with Combination PDS0101-KEYTRUDA® is Now Open and Recruiting Patients
See the article here:
PDS Biotech Initiates VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Recurrent/Metastatic Head and Neck Cancer in Collaboration with...
CANTON, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the three and nine months ended September 30, 2020.
Read more:
Organogenesis Holdings Inc. Reports Third Quarter and Nine Months 2020 Financial Results
GAITHERSBURG, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and nine months ended September 30, 2020 and provided a business update.
Read more here:
Altimmune Announces Third Quarter 2020 Financial Results and Provides a Business Update
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today financial results for the three and nine months ended September 30, 2020 and provided an update on key initiatives.
Visit link:
Tricida Announces Third Quarter 2020 Financial Results
Reported 84 thousand tests in the third quarter, up 12% compared to the second quarter
Read this article:
Progenity Provides Corporate Updates and Reports Third Quarter 2020 Financial Results
Expansion in international and seed treatment markets led revenue growth and gross margin improvement Expansion in international and seed treatment markets led revenue growth and gross margin improvement
More here:
Marrone Bio Innovations, Inc. Reports Third-Quarter 2020 Financial Results
Sydney, Australia, Nov. 10, 2020 (GLOBE NEWSWIRE) -- ASX/Media Release
See the rest here:
Immutep’s Phase II TACTI-002 Study Reports Encouraging Data at SITC
NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2020 and recent company developments.
Read more:
TG Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results